Orion Corporation

• Bioequivalence study comparing two temazepam 20 mg tablet formulations after fasted administration; an open, randomized, single centre, sing… Pending
  2025-524376-36-00 1 country
• Trial to study the safety and pharmacokinetics of ODM-212 combined with existing cancer treatments Pending
  2025-524620-22-00 Phase I/II 4 countries (S)-N-(2-METHOXY-5-((5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)PHENYL)-3-METHYL-2-OXOI…
• Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers Pending
  2026-525448-14-00 1 country
• FIRST IN-HUMAN STUDY EVALUATING THE EFFECT OF VARIOUS DOSES OF ODM-212 IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMOURS Recruiting
  2022-503061-29-00 Phase I (FiH) 3 countries ODM-212
• Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers Ended
  2026-525449-57-00 1 country
• UNITAS Ended
  2022-502483-21-00 Phase II 3 countries TASIPIMIDINE
• Safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer Ended
  2024-517439-39-00 Phase I (FiH) 2 countries ODM-208; OPEVESOSTAT
• CHRONOS - A study to learn about the effects and safety of ODM-111 in participants with long-lasting pain due to osteoarthritis of the knee. Ended
  2024-513553-79-00 Phase II 5 countries ODM-111; PARACETAMOL
• CHRONDI Ended
  2024-513595-17-00 Phase II 5 countries ODM-111; PARACETAMOL

Showing 1–9 of 9 trials